IntriCon (NASDAQ:IIN) Stock Rating Upgraded by Zacks Investment Research
According to Zacks, “IntriCon designs, develops, engineers and manufactures microminiaturized medical and electronic products. The Company supplies microminiaturized components, systems and molded plastic parts, primarily to the hearing instrument manufacturing industry, as well as the computer, government, electronics, telecommunications and medical equipment industries. The Company has facilities in the United States, Asia and Europe. “
A number of other equities analysts have also commented on the company. Stifel Nicolaus set a $36.00 price objective on IntriCon and gave the stock a buy rating in a research note on Friday, July 19th. B. Riley set a $6.00 price objective on Intevac and gave the stock a hold rating in a research note on Friday, July 19th. Finally, ValuEngine lowered Whiting USA Trust II from a hold rating to a sell rating in a research note on Tuesday, May 7th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of Buy and an average target price of $38.75.
IntriCon (NASDAQ:IIN) last posted its quarterly earnings data on Monday, April 29th. The technology company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The business had revenue of $30.11 million during the quarter, compared to analyst estimates of $30.05 million. IntriCon had a return on equity of 7.39% and a net margin of 4.58%. As a group, equities analysts forecast that IntriCon will post 0.23 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA acquired a new position in shares of IntriCon during the first quarter valued at $40,000. Conestoga Capital Advisors LLC acquired a new position in shares of IntriCon during the first quarter valued at $235,000. Rhumbline Advisers lifted its stake in shares of IntriCon by 58.9% during the fourth quarter. Rhumbline Advisers now owns 9,104 shares of the technology company’s stock valued at $240,000 after acquiring an additional 3,375 shares during the period. Brasada Capital Management LP acquired a new position in shares of IntriCon during the first quarter valued at $251,000. Finally, Paloma Partners Management Co acquired a new position in shares of IntriCon during the fourth quarter valued at $264,000. 72.51% of the stock is currently owned by institutional investors and hedge funds.
IntriCon Company Profile
IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company operates in two segments, Body Worn Devices and Hearing Health Direct-To-Consumer. It offers micro-miniature products, microelectronics; micro-mechanical assemblies; high-precision injection-molded plastic components; and assemblies and software solutions for medical biotelemetry devices, hearing healthcare, and professional audio communication devices markets.
Further Reading: How is the discount rate different from the Federal Funds rate?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IntriCon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntriCon and related companies with MarketBeat.com's FREE daily email newsletter.